Sector News

Dr. Deborah Dunsire named new President and CEO of Lundbeck

July 2, 2018
Life sciences

H. Lundbeck A/S today announced that the Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Dr. Dunsire will take up her new position on 1 September 2018.

Trained as a medical doctor, Deborah Dunsire (56) is an experienced CEO who brings more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS, thus bridging a breadth of scientific and business experience. Her wealth of professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc.

“It is a great pleasure to announce that Deborah Dunsire will join Lundbeck as President and CEO,” says Lars Rasmussen, Chairman of Lundbeck’s Board of Directors. “She brings a wealth of highly successful R&D and commercial experiences including a robust knowledge and experience in neuroscience. She is a proven and highly passionate leader and has all the qualifications to take Lundbeck to the next level as a global leader within psychiatric and neurological disorders.”

Dr. Dunsire has lived in the U.S. since 1994, and grew up in South Africa where she graduated from University of the Witwatersrand, Johannesburg, in 1985. In connection with her new position, Dr. Dunsire plans to move to Denmark from the U.S.

“Lundbeck stands out in the industry as a global company with a great history of innovating in neuroscience, which is recognized to be one of the toughest research areas for the industry “, says Dr. Dunsire and continues “I am excited to bring my experience to help build an even stronger and brighter future for Lundbeck, patients, employees, partners and shareholders.”

From 1 September 2018, Anders Götzsche, interim CEO and CFO in Lundbeck will resume his position as CFO for the company.

“Anders has held the position as interim CEO since November 2017, and has together with the rest of management team done an excellent job in continuing the strong positive development that Lundbeck is having,” says Lars Rasmussen, Chairman of Lundbeck’s Board of Directors. “The Board will like to express gratitude for a job well done and we look forward to see Lundbeck continuing the positive development under the new management team.”

Source: Lundbeck

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend